Evidence map›Paper›PMID 32895164›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2020

[Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis].

Yubin Fan, Rongling He, Lijun Zou, Jie Meng

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yubin FanDepartment of Respiratory and Critical Care Medicine, Xiangya Hospital; Organ Fibrosis Research Center, Central South University, Changsha 410008, China.
Rongling HeDepartment of Respiratory and Critical Care Medicine, Xiangya Hospital; Organ Fibrosis Research Center, Central South University, Changsha 410008, China.
Lijun ZouDepartment of Respiratory and Critical Care Medicine, Xiangya Hospital; Organ Fibrosis Research Center, Central South University, Changsha 410008, China.
Jie MengDepartment of Respiratory and Critical Care Medicine, Xiangya Hospital; Organ Fibrosis Research Center, Central South University, Changsha 410008, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia characterized by progressive accumulation of fibroblastic foci and destruction of the alveolar structure. Due to an incomplete understanding of the mechanism of the occurrence and progression of IPF, currently no effective means have been available for its early screening or treatment. With a poor overall prognosis, the patients with IPF have a median survival of only 2-4 years. In recent years, several studies have confirmed that dozens of molecules are involved in the development of IPF and can be used as potential biomarkers. These biomarkers play important roles in early diagnosis (such as SP-D, MMP-7, and osteopontin), prognostic evaluation (such as telomerase length, KL-6, mtDNA, HSP-70, LOXL2, CXCL13, miRNA, ICAM-1, and CCL18), and guiding treatment of IPF (such as TOLLIP rs3750920 genotype, SAMS score, and SP-D), and also provide potential therapeutic targets (such as TERT, TERR, RTEC, and PARN).

Indexed as

Idiopathic Pulmonary FibrosisAmino Acid OxidoreductasesBiomarkersDisease ProgressionHumansIntracellular Signaling Peptides and ProteinsMatrix Metalloproteinase 7PrognosisAmino Acid OxidoreductasesBiomarkersIntracellular Signaling Peptides and ProteinsLOXL2 protein, humanMatrix Metalloproteinase 7TOLLIP protein, humanbiomarkerdiagnosisIdiopathic pulmonary fibrosisprognosis

Identifiers

PMID32895164
PMCPMC7386223
OpenAlexW3084313007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.